We are live on ! Find out more

Bluejay Diagnostics

BJDX

Market cap $2.49M

0.5564 USD

+0.0161

2.98%

At close Updated Oct 30, 4:00 PM EDT

1 day

2.98%

5 days

-5.87%

1 month

-34.92%

3 months

-40.13%

6 months

-69.26%

Year to date

-78.76%

1 year

-93.68%

5 years

-100%

10 years

-100%

About: Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.

Employees: 6

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 20%

Neutral 80%

Negative 0%

Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization Readiness

Company Achieves Toray Contractual Milestone with Establishment of Manufacturing Site ACTON, MA / ACCESS Newswire / October 13, 2026 / Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient diagnostic platform, today announced that it has completed the establishment of a manufacturing site for Symphony™ cartridges, achieving a critical contractual milestone as the Company advances toward regulatory submission and potential commercialization. The milestone was achieved ahead of the October 23, 2026 contractual deadline established under Bluejay's amended license agreement with Toray Industries, Inc. ("Toray").

Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization Readiness

Bluejay Diagnostics Advances Rapid Biomarker Testing For Sepsis Patients

Bluejay Diagnostics Inc. (NASDAQ:BJDX), through its Symphony near-patient diagnostic platform, on Tuesday revealed foundational clinical data from its SYMON-II validation trial.

Bluejay Diagnostics Advances Rapid Biomarker Testing For Sepsis Patients

Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock

SYMON-II Clinical Validation Dataset Represents a Key Milestone as Bluejay Advances the Symphony™ IL-6 Test Toward Regulatory Submission ACTON, MA / ACCESS Newswire / October 6, 2026 / Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient diagnostic platform, today announced baseline clinical characteristics from the SYMON-II clinical validation study, highlighting a substantial and diverse population of critically ill patients and clinically meaningful mortality events for evaluating interleukin-6 ("IL-6") as a biomarker associated with 28-day mortality risk in patients with sepsis and septic shock. The current preliminary SYMON-II analysis includes 777 evaluable patients, consisting of 637 28-day survivors and 140 28-day non-survivors, representing an overall 28-day mortality rate of approximately 18%.

Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock

Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets

Partnership Establishes Federal Distribution and Co-Marketing Framework Across VA, DoD, Military Health Systems and Other Government Healthcare Channels Partnership Establishes Federal Distribution and Co-Marketing Framework Across VA, DoD, Military Health Systems and Other Government Healthcare Channels

Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

ACTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes in critical care settings, today reported financial results for the quarter ended June 30, 2026 and provided an update on the Company's clinical, regulatory and manufacturing progress.

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study

750 Patients Enrolled Ahead of Plan in Pivotal Study Evaluating Symphony™ IL-6 for Early Assessment of 28-Day Sepsis Mortality Risk 750 Patients Enrolled Ahead of Plan in Pivotal Study Evaluating Symphony™ IL-6 for Early Assessment of 28-Day Sepsis Mortality Risk

Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

What's Going On With Bluejay Diagnostics Shares On Wednesday?

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) shares are trading lower on Wednesday. On Tuesday, the company disclosed a private placement that aims to raise up to $23.6 million.

What's Going On With Bluejay Diagnostics Shares On Wednesday?

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

$8.5 million upfront with up to approximately $15.1 million of potential additional gross proceeds upon the exercise in full of warrants

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

ACTON, Mass. and CARLSBAD, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”) (NASDAQ: BJDX), a medical diagnostics company focused on near-patient testing for critical care, today announced a strategic partnership with Argonaut Manufacturing Services (“Argonaut”) to support the advancement of Bluejay's Symphony™ platform.

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

See News Rankings

Price charts implemented using Lightweight Charts™